Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)
CompletedOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
December 31, 2011
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
Conditions
Exudative Age-Related Macular Degeneration
Trial Locations (1)
63141
The Retina Center, St Louis
All Listed Sponsors
collaborator
ZeaVision, Inc.
INDUSTRY
lead
The Retina Center of St. Louis County, PC
OTHER
NCT01527435 - Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD) | Biotech Hunter | Biotech Hunter